Semaglutide's Effect on Renal Hemodynamics and Function in Patients With Type 2 Diabetes Mellitus and Nephropathy

Sponsor
Bispebjerg Hospital
Study ID
NCT06555146
Status
Unknown

Conditions

Eligibility Criteria

Sex
MALE
Age
20 Years - 60 Years
Healthy Volunteers
Not accepted

Interventions

  • Semaglutide, 0.5 mg/mL — DRUG
    1 subcutaneous injection on baseline day
  • Placebo, Saline — DRUG
    1 subcutaneous injection on baseline day

Study Details

The goal of this double-blinded, placebo-controlled, randomized, crossover study is to examine the effect of semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), on renal hemodynamics and function in patients with type 2 diabetes mellitus (T2DM) and moderate chronic kidney disease (CKD). The study will determine the effects of semaglutide on: * Renal arterial blood flow, regional renal perfusion, and oxygenation * Activity of the renin-angiotensin-aldosterone system (RAAS) * The glomerular filtration rate (GFR) * Sodium excretion in urine * Blood pressure and heart rate

Key Dates

First listed
Aug 15, 2024
Start date
Aug 31, 2024
Status verified
Aug 2024
Primary completion
Mar 31, 2025
Completion
Mar 31, 2025

Study Design

Enrollment
15 participants (estimated)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE

Arms

  • Other: Randomized to start with Semaglutide intervention in study period 1
    Placebo will be given in study period 2
  • Other: Randomized to start with Placebo intervention in study period 1
    Semaglutide will be given in study period 2

Primary Outcome Measure

Total blood flow [ Time Frame: Measured during 30 minutes of MRI. One measurement will be done on each study day, a total of 4 measurements for each participant, over the span of the study (approximately 1 year). ]

Central Contacts

Find similar trials

Nationwide
Type 2 diabetes trialsEndocrinology trialsMetabolic health trialsWeight loss trials

Related Studies